Alerts
What is the gut microbiota-bone axis? Recent advances and perspectives
One of the strategic question of Targeting Microbiota 2016 will be "What is the gut microbiota-bone axis?"
This strategic question will be answered by Dr Elena Comelli, Lawson Family Chair in Microbiome Nutrition Research, Faculty of Medicine, University of Toronto, Canada.
She will also highlight the mechanisms underlined by the gut microbiota-bone axis and will answer the question "Can we use diet to beneficially impact this axis?"
If you are interested to know more about this strategic topic, come and register on www.microbiota-site.com
The butyrate revival. Short chain fatty acids as key mediators of gut microbiota
Pr Hervé Blottière,
the Director of Research at INRA, the French National Research Institute for Agricultural and Food Research, will join the 4th Congress on Targeting Microbiota and present his research topic of "The butyrate revival. Short chain fatty acids as key mediators of gut microbiota".
The following questions will be discussed during the congress:
- Is depletion of butyrate metabolic pathway genes in gut microbiome a common trait of disease-associated dysbiosis?
- Can we consider short chain fatty acids as essential cell-signaling modulators in host cells through Lysine/Histone Deacetylase inhibition and G-protein coupled receptor activation ?
- What is the effect of SCFA on the intestinal immune cells ?
If you are interested to know more about Pr Blottière's researches, do not hesitate to join the participants by registering here: www.microbiota-site.com
Transition from an infant- to adult-like gut microbiota – where do the bacteria come from?
During the 4th World Congress on Targeting Microbiota, Dr Ekaterina Avershina, from the Norway University of Life Sciences will talk about the "Transition from an infant- to adult-like gut microbiota – where do the bacteria come from?".
During her presentation, she will highlight and answer for following questions:
- How can we determine the number of bacterial strains colonizing the human gut?
- What are the main vectors for horizontal gene transfer of antibiotic resistance in the gut?
- What are the taxonomic associations for horizontal gene transfer in the gut?
If you are interested to know more about this strategic topic, you can register for the 4th World Congress on Targeting Microbiota by clicking here.
The International Society of Microbiota
www.microbiota-site.com
The challenge of the bioinformatics, integrating clinical and microbiome data will be discussed during Targeting Microbiota Congress 2016
During Targeting Microbiota World Congress 2016, Dr Velma Aho from the University of Helsinki will take about the challenge of the bioinformatics, integrating clinical and microbiome data. She will especially present the examples from gut, oral and nasal microbiota in Parkinson's disease.
At the end of Dr Aho's presentation, the following questions will be answered:
- What to consider when designing a microbiome study?
- How to integrate clinical and microbiome data?
- What can we say about the associations between Parkinson’s disease and gut, oral and nasal microbiota?
If you are interested to know more about bioinformatics and microbiota data management, you can join the participants of Targeting Microbiota World Congress by registering here.
Marvin Edeas, Chairman of ISM
Maternal microbiota sets neonatal innate immune system development
Dr Mercedes Gomez de Agüero from the University of Bern in Switzerland was invited by the scientific committee of the International Society of Microbiota to present her researches about the maternal microbiota and the neonatal innate immune system development.
The following questions will be answered by Dr Gomez during the congress:
- When the impact of the microbiota in the development of the immune system starts?
- What is the role played by the maternal antibodies in the impact of maternal microbiota in the development of neonatal immune system?
- Which kind of bacterial products would be involved in the effect of maternal microbiota in the shaping of the neonatal immune system?
According to Dr Gomez, Mammalian, born from a sterile environment in the maternal uterus, get colonized by a millions of microorganism at birth. How the immature neonatal immune system of the newborn is prepared to this colonisation was not clearly understood. Using an auxotrophic genetically modified strain of Esc Maternal microbiota sets neonatal innate immune system development herichia coli, we reversible colonised pregnant germ free mice and analysed by flow cytometry and RNA sequencing the impact of maternal microbiota on the development of immune system in the pups. [...] The offspring from gestational colonized mothers were protected against microbiota challenge preventing bacterial translocation to mesenteric lymph nodes and modulating gene expression. Our results reveal the tremendous role played by maternal microbiota and antibodies in setting the baseline of the innate immune system in the neonates.
For more information about this strategic topic, don't hesitate to register on www.microbiota-site.com
Important human microbial ecological system modulator - FMT or one of the best clinical applications of epigenetics in gastroenterology
During Targeting Microbiota World Congress 2016, Dr. Diana Zandere from the University of Riga, Latvia will talk about the important human microbial ecological system modulator - FMT (fecal microorganism transplantation) or one of the best clinical applications of epigenetics in gastroenterology.
At the end of Dr Zandere's presentation, the following questions will be answered:
- Have there been FMT donor selection with appropriate donor-recipient sex matching (i.e.young female to female, young male to male and so on) in order to enhance FMT colonization success?
- Should donors or recipients adhere for a certain period of time to agluten diet for better therapeutic gain (think zonulin-occludin systems and/or N-(phosphonomethyl) glycine?
- Is nutritional background as an important GI microbiome modulator & epigenetic modulator being investigated enough in connection to FMT and/or probiotic or sinbiotic "loading"? Polypharmacy + probiotics without true enteric coating + frozen unmatched FMT donor material + long term nutritional management absent +xenoestrogens+ recipient with organ deficiency=...?
If you are interested to know more about human microbial ecological system, you can join the participants of Targeting Microbiota World Congress by registering here.
Marvin Edeas, Chairman of ISM
Bacteriocin from epidemic Listeria strains alters the host intestinal microbiota to favor infection
The scientific committee of the International Society of Microbiota invited Dr Juan José Quereda from the Institut Pasteur to give a talk about Bacteriocin from epidemic Listeria strains alters the host intestinal microbiota to favor infection.
During his talk, Dr Quereda will answer the following questions:
1) Does Listeria monocytogenes produce any bacteriocin and where is it produced?
2) Does this bacteriocin alter the host intestinal microbiota?
3) Does this bacteriocin impact the infectious potential of the producing L. monocytogenes strains?
If you are interested to know more about this strategic topic, you can register for the 4th World Congress on Targeting Microbiota by clicking here.
Marvin Edeas - Chairman of ISM
The International Society of Microbiota
www.microbiota-site.com
Bacteriophages for improving human health: from food additives to dietary supplements
The scientific committee of the International Society of Microbiota is honoured to welcome Dr. Alexander Sulakvelidze, Editor-in-chief of Bacteriophage for the 4th edition of Targeting Microbiota World Congress.
During the congress, Dr. Sulakvelidze will talk about bacteriophages for improving human health: from food additives to dietary supplements. According to Dr. Sulakvelidze, the emergence of drug-resistant bacteria has rekindled interest in potential utility of lytic bacteriophages for managing bacterial infections. While most public attention has focused on the use of phages for treating human infections, there are currently no FDA-approved phage products available for human therapeutic applications. It is anticipated that such products will be gradually approved and marketed over the next several years. Meanwhile, lytic bacteriophages are already improving our health by enhancing our food safety; e.g., several FDA-approved phage-based products are currently on the market for “phage biocontrol” applications. Moreover, application of bacteriophages as dietary supplements / probiotics is also gaining an increased attention, as phages are increasingly being considered for targeted fine-tuning of the human microbiota for health benefits.
The presentation will give the audience a current perspective about the history of bacteriophage therapy research and the crucial regulatory and human safety issues concerning the use of bacteriophages in various applications ranging from food safety (“phage biocontrol”) to dietary supplements / probiotics.
For more information please visit: www.microbiota-site.com
Role of the microbiome in inflammatory bowel diseases: using multi-omics datase
The microbial ecosystem residing in the human gastrointestinal tract plays an intimate role in the development and well-being of their human host. The gut commensal microbes reside in synergy with the host, undertaking wide range of functions that benefits themselves and their host. These host-associated microbial communities that share different functional genes between distinct bacterial species are increasingly associated with horizontal gene transfer (HGT).
During Targeting Microbiota World Congress, Dr Knut Rudi from the Norwegian University of Life Sciences will discuss the current status and future developments in their knowledge about the infant gut microbiota mobilome will be discussed.
Marvin Edeas from Institut Cochin, INSERM U1016 will present the challenge to find strategies to modulate the quality and diversity of microbiota
Our aim is to highlight the subtle relationship that exists between microbiota and mitochondria. Microbiota targets mitochondria by modulating the Reactive Oxygen Species (ROS) production and the mitochondrial activity through interactions with toxins, proteins or other metabolites released by gut microbiota. The intriguing relationship that exists between mitochondria and microbiota is strengthened by the probable prokaryotic origin of mitochondria. Emerging data implicates a role for ROS, nitric oxide, Short Chain Fatty Acids and hydrogen sulfide in the cross-talk between microbiota – mitochondria and REDOX signaling. Several studies have shown that microbiota act and modulate mitochondrial activity, and use it as a relay to strengthen host-microbiotal interaction. This modulation depends on the gut bacterial strain quality and diversity to increase its pathogenic versus beneficial effects. Furthermore, based on conclusions from new studies, it is possible that microbiota can directly interact with the host cell gene expression by favoring bacterial and mitochondrial DNA insertion in the nuclear genome. The emerging knowledge of mitochondria-microbiota interaction may be of great importance to better understand the mechanism of mitochondrial and metabolic diseases, and the syndromes associated with change in quality and quantity of microbiotal species. We suggest that microbiota via mitochondrial modulation influence cell homeostasis and metabolism. The challenge will be to find strategies to modulate the quality and diversity of microbiota rather than acting on microbiota metabolites and microbiota related factors. The medicine of tomorrow will be completely personalized. Firstly there will be a test to show the quality, quantity and diversity of microbiota, and secondly a preventive or therapeutic strategy will be administrated (probiotics, diet, prodrug or fecal transplantation). The era of digital medicine is here.
References :
Weissig, V. and Edeas, M., Mitochondrial medicine Vol. I Probing mitochondrial function. Preface. Methods Mol Biol. 2015, 1264
Weissig, V. and Edeas, M., Mitochondrial medicine. Vol. II Manipulating mitochondrial function. Preface. Methods Mol Biol. 2015, 1265
Dr Sean Kennedy, Institut Pasteur, Department of Genome & Genetics will highlight microbiota analysis and bioinformatics
Dr Sean Kennedy will chair the session about microbiota analysis and bioinformatics.
The scientific committee of ISM believes that bio-informaticians will play the most strategic role to interpret the microbiome and microbiota analysis.
Dr. Jasper will hightlight the age-related immune senescence and microbiota dysbiosis
Dr. Henri Jasper, Professor and CSO of the Buck Institute for Research on Aging in Novato, Canada, will give a presentation about Age-related immune senescence and microbiota dysbiosis: lessons from the fly, on the 4th World Congress on Targeting Microbiota.
Dr. Jasper’s lab studies the effects of aging on the intestinal microbiota, using Drosophila as a genetically accessible model system. Recent studies have uncovered a critical role for immune deregulation in the development of microbiota dysbiosis in aging animals. The work established that the intestinal epithelium of aging flies develops an inflammatory condition that is characterized by hyper activation of the Relish-NFkB signaling pathway, and results in expansion of the commensal microbiota, a secondary inflammatory response, and over-activation of intestinal stem cell proliferation. By preventing NFkB deregulation, the authors are able to delay these phenotypes and extend lifespan. Current work focuses on age-related changes in microbiota composition and compartmentalization, and new findings will be presented at the conference.
Find more information about the congress here: http://www.microbiota-site.com/
Dr. Jasper’s lab studies the effects of aging on the intestinal microbiota, using Drosophila as a genetically accessible model system. Recent studies have uncovered a critical role for immune deregulation in the development of microbiota dysbiosis in aging animals. The work established that the intestinal epithelium of aging flies develops an inflammatory condition that is characterized by hyper activation of the Relish-NFkB signaling pathway, and results in expansion of the commensal microbiota, a secondary inflammatory response, and over-activation of intestinal stem cell proliferation. By preventing NFkB deregulation, the authors are able to delay these phenotypes and extend lifespan. Current work focuses on age-related changes in microbiota composition and compartmentalization, and new findings will be presented at the conference.
The Challenges to control the diversity and variability of microbiota
During Targeting Microbiota 2016, the scientific committee will allocate time to discuss the challenges to control the diversity and variability of microbiota.
Among the challenges which will be discussed:
- Phage therapy
- Diet, probiotics and prebiotics
- CRISPR/Cas system
- Quorum sensing
- Fecal Microbiota Transplantation: Clinical & Practical Issues
A special session will be specifically dedicated to the fecal microbiota transplantation. For more information, please click here.
If you are interested to submit your abstracts related to these challenges, please click here.
For more information about Targeting Microbiota 2016: www.microbiota-site.com
A session is dedicated to the Microbiota analysis 2016: The challenge of big data interpretation
The Scientific Committee decided to organize a special session about Microbiota analysis 2016: The challenge of big data interpretation.
Skin microbiota: Towards a new era in dermocosmetics/ Dermatology
This review was based on symposium on skin microbiota which was organized by the International Society of Microbiota on June 17, 2015, Paris, France. Marvin Edeas, Chairman of the Scientific Committee of ISM stated: "This review shortly characterises skin microbiota and their functions. The impact of external factors such as xenobiotics, traumatization, UVB light, cosmetic products and antiseptics are discussed. Strategies to target axillary microbiota to prevent body odour, as well as potential targets to manipulate microbiota in cosmetics and athopic dermatitis are outlined with examples. In future we may expect that knowledge of skin microbionome will allow development of wide range of cosmetical products and stratify patient and people with high predispostion to disease subsets, predict the best treatment or preventiv modality and outcome and introduce new treatment strategies by targetely manipulation of microbial communities."
To access to this review, please contact ISM.
Targeting Microbiota Abstract Submission
Submit your abstracts to be featured in the Targeting Microbiota 2024 Book of abstracts allocated with a DOI, guaranteeing your work a permanent and easily accessible online presence. Read more.
Deadline for Short Oral Presentation Abstract Submission:
October 1, 2024
Deadline for Poster Presentation Abstract Submission:
October 4, 2024
Submission Guidelines:
- Submit abstracts to the Scientific Committee.
- Use the online form for submissions. Abstracts not using this form will not be considered.
- One abstract per registered person.
- For oral submissions: prioritize in-person presentations. Online presentations require prior approval.
- Online poster submissions are accepted.
- No changes after the submission deadline.
- Abstracts cannot be modified post-acceptance.
Abstract Format:
- Title: Max 20 words.
- Text: Max 200 words, divided into Introduction, Materials & Methods, Conclusion.
- Define unusual abbreviations on first use.
- Relate to conference tracks or sessions, and specify the topic.
- Include references (max 3).
- Submit in both Word and PDF formats, prepared in B5 format.
Download abstract format guidelines here in Word or in PDF.
Abstracts not following the formalities will not be considered.
Reviewing and Selection Process
- All submissions reviewed by the Scientific Committee.
- Selection based on originality, novelty, impact (score 1-10).
- Scores 9-10: considered for oral presentation.
- Scores 6-8: accepted for poster presentation.
- Preference for in-person short oral presentations.
- E-posters can be accepted.
- Low-quality or off-topic abstracts may be rejected.
Published Abstracts
Accepted abstracts will be published in the conference abstracts book.
Short Oral Presentations
- Duration: 7 minutes presentation, 3 minutes Q&A.
- Slide limit: 8 slides (+1 for title).
- Cover research aim, methods, results, conclusion.
- Timing subject to final program adjustments.
Posters Session
- Format: A1 vertical (84.1cm x 59.4cm).
- Presented during coffee and lunch breaks.
- E-posters to be emailed to: microbiota[at]microbiota-ism.com
The ISM awarded Pr Iradj Sobhani for his Scientific Contribution during the 3rd World Congress on Targeting Microbiota
During the 3rd World Congress on Targeting Microbiota held at Pasteur Institute from October 21 to 23, Pr Iradj Sobhani from Hôpital Universitaire Henri Mondor, France gave a strategic presentation about "Cancer & Microbiota: Potential of fecal microbiota for early-stage detection of colorectal cancer".
According Pr Sobhani: "Colorectal cancer (CRC) is one of the main major problems in health care. The incidence is growing in western countries and no evident cause is found although germline DNA mutations in less than 5% of patients are identified and environment factors such as food, style of life, medicine, etc... are now suspected to induce majority of cancers. Exhaustive quantitative and qualitative evaluation of all factors from the environment is not possible. The microbiota may be considered as platform offering host and environment interactions for studying CRCs. And growing data show specific changes in microflora (dysbiosis) in colon cancer patients’ stools or adherent to the colonic mucosa. The hypothesis that colon cancer might be a bacteria-related disease is suggested and perspectives discussed."
The Scientific Committee of the International Society of Microbiota was delighted to award Pr Sobhani for this strategic presentation and his scientific contribution during the international congress.
For more information about the congress: www.microbiota-site.com
ISM is pleased to award three scientists for their oral and poster presentations
The Scientific Committee of the International Society of Microbiota awarded three scientists for their presentations during Targeting Microbiota World Congress which was held in Institut Pasteur, Paris:
- Dr Atti-La Dahlgren, Sweden for her short oral presentation about "Anaerobically Cultivated Human Intestinal Microbiota"
- Dr Heenam Stanley Kim, from Korea for his poster about "Subspecies-level dysbiosis of Faecalibacterium prausnitzii in the human gut microbiome underlies atopic dermatitis"
- Dr Erica Castro de Lourdes, Columbia, for her poster about "Selection of lactic acid bacteria for the prevention of dental caries"
If you would like to access to the abstracts of these three presentations, you can order the abstracts book by clicking here.
For more information about Targeting Microbiota 2015: www.microbiota-site.com
Dr Gurumoorthy Krishnamoorthy was awarded by the Scientific Committee of ISM for his Scientific Contribution
It is an honor to announce the award discerned by The Scientific Committee of ISM to Dr Gurumoorthy Krishnamoorthy from Max Planck Institute of Neurobiology, Germany for his scientific contribution about "The gut-brain axis in the CNS autoimmunity", during Targeting Microbiota 2014.
Dr Atti-La Dahlgren was awarded for his presentation about Anaerobically cultivated human intestinal microbiota
Dr. Dahlgren is a Swedish physician specialised in International Public Health and is affiliated to Karolinska Institutet Department of Microbiology, Tumor and Cell biology, in Stockholm Sweden. His current field of research is the clinical application of Anaerobically Cultivated Intestinal Microbiota, especially in Recurrent Clostridium difficile infections, a major public health concern in US, Canada, Europe and other countries. Since 2003 he in an advisor to the Bhutan Health Trust Fund and the Ministry of Health in the Kingdom of Bhutan.
During Targeting Microbiota World Congress 2005, Dr Dahlgren gave a short oral presentation about "anaerobically cultivated human intestinal microbiota".
For almost 20 years, Dr Dahlgren's team have produced a human intestinal microbiota under strict anaerobic conditions, as an in vitro batch culture. This cultivated microbial ecosystem designated anaerobic cultivated human intestinal microbiota (ACHIM) has been reinoculated every second week during the years into new production batches. The cultivated microbiota has retained a microbial diversity comparable to that of feces from healthy donors, containing the major bacterial phyla Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria, as confirmed by gene sequencing.This batch-cultured microbial ecosystem has been tested for safety and clinical efficacy for many years in more than 400 patients, most of them suffering from recurrent Clostridium difficile-infection (RCDI). [...]
The scientific committee was honoured to award Dr Dahlgren for this strategic study.
If you would like to access to the complete abstract, and to the complete abstracts book, you can order it by clicking here.
Targeting Microbiota Congress Great moments in Picture
Targeting Microbiota World congress was a exciting moment, where speakers and participants shared scientific knowledge in Microbiota.
You can find here some pictures of this three-days congress.
More Articles...
- The Scientific Committee published the final agenda of Targeting Microbiota World Congress
- The Subltle Balance Between Body Fat, Gut Microbiota and the Brain
- To Swab or Not to Swab? Rectal Swabs for Intestinal Microbiota Analysis
- Who will attend Targeting Microbiota World Congress 2015 from Industries & Academics?
